Contribution of whole‑ body magnetic resonance in the diagnostics of monoclonal gammopathy of undetermined significance, multiple myeloma, and the assessment of Durie‑ Salmon Plus staging system

Česká verzia

Authors: V. Ščudla ¹; M. Heřman ²; J. Minařík ¹; T. Pika ¹; J. Hrbek ²; J. Bačovský ¹; V. Heinzová ³
Authors place of work: III. interní klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MU Dr. Vlastimil Ščudla, CSc. ¹; Radiologická klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MU Dr. Miroslav Heřman, Ph. D. ²; Hematologické a transfuzní oddělení Slezské nemocnice Opava, přednostka prim. MU Dr. Dagmar Adamová ³
Published in the journal: Vnitř Lék 2011; 57(1): 52-60
Category: Original Contributions

Summary

Background:
The aim of the study was to assess the contribution of the whole body MRI (WB‑ MRI) in the diagnostics of monoclonal gammopathy of undetermined significance (MGUS) and initial, asymptomatic form of multiple myeloma (MM), as well as the evaluation of practical usefulness of the Durie‑ Salmon Plus staging system (D‑S Plus).

Materials and methods:
The analyzed 86- patient cohort consisted of 28 patients with MGUS and 54 patients with newly diagnosed multiple myeloma and 4 patients with solitary plasmocytoma (SP). WB‑ MRI was evaluated using Magnetom Avanto 1.5 T with the use of virtual whole body coil with sequential acquisition on 7 levels and 2 sequentions – T2 STIR and T1. Based on the number of lesions and the degree of diffuse involvement we assessed the D‑S Plus stage, and compared it to the results of standard staging systems according to Durie Salmon (D‑S) and International Staging System (ISS). Statistical estimation was done using the Cohen κ test and McNemara‑Bowker test at p < 0.05.

Results:
In the group of 28 individuals with MGUS, there were 17 (61%) patients fulfilling the IMWG criteria and/ or WB‑ MRI criteria of incipient MM. In 4/ 17 (23%) patients we described a more advanced stage when comparing D‑S Plus to D‑S. Nine out of fourteen (64%) patients with MGUS transforming into MM with negative radiological assessment had positive findings on WB‑ MRI. The character of WB‑ MRI findings lead in 9/ 17 (53%) of the patients to the initiation of induction treatment. Stratification according to D‑S Plus divided the 54 newly diagnosed patients with MM into stage 1 (16.7%), stage 2 (33.3%) and stage 3 (50%). In 22 % there was a shift into a higher stage using DS‑ Plus in comparison with D‑S, in 9% of the patients the shift lead to downstaging. When comparing the results of ISS vs D‑S Plus we found that the system based on WB‑ MRI showed in 41% of the patients higher stage and only in 9% of the patients lower stage. In 13% of MM patients we described extramedulary masses of the tumor, especially in paraspinal region. In 1 of the 4 SP patients the WB‑ MRI changed the diagnosis into multifocal plasmocytoma.

Conclusion:
WB‑ MRI is a very contributive imaging method with substantially higher resolution than conventional radiography. It is able to evaluate the grade and the extent of myeloma bone disease. It improves the diagnostic approach in the differentiation of stable MGUS from the phase of malignant transformation into MM. The D‑S Plus system proved to be contributive and is competent to become a routine part of diagnostic and stratification algorithms in MGUS and MM.

Key words:
monoclonal gammopathy of undetermined significance – multiple myeloma – whole- body MRI – Durie‑ Salmon Plus – Durie Salmon Staging System – International Staging System

Zdroje

1. Hájek R, Adam Z, Maisnar V et al, Česká myelomová skupina. Souhrn doporučení 2009 „Diagnostika a léčba mnohočetného myelomu“. Transfuze Hematol dnes 2009; 15 (Suppl 2): 1– 80.

2. Ščudla V. Současné možnosti léčby mnohočetného myelomu. Remedia 2009; 19: 410– 419.

3. International Myeloma Working Group. Criteria for the clasification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Brit J Haematol 2003; 121: 749– 757.

4. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842– 854.

5. Shortt CP, Gleeson TG, Breen KA et al. Whole- body MRI versus PET in assessment of multiple myeloma disease activity. AJR 2009; 192: 980– 986.

6. Fonti R, Salvatore B, Quarantelli M et al. 18F- FDG PET/ CT, 99mTc- MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med 2008; 49: 195– 200.

7. Hur J, Yoon CS, Ryu YH et al. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma. Acta Radiologica 2008; 46: 427– 435.

8. Mulligan ME, Badros AZ. PET/ CT and MR imaging in myeloma. Skeletal Radiol 2007; 36: 5– 16.

9. Lütje S, de Rooy WJ, Croockewit S et al. Role of radiography, MRI and FDG- PET/ CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. Ann Hematol 2009; 88: 1161– 1168.

10. Durie BGM. The role of anatomic and functional staging in myeloma: Description of Durie/ Salmon Plus staging system. European Journal of Cancer 2006; 42: 1539– 1543.

11. Baur A, Stäbler A, Nagel D et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002; 95: 1334– 1345.

12. Bäuerle T, Hillengass J, Fechtner K et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: Importance of whole- body versus spinal MR imaging. Radiology 2009; 252: 477– 485.

13. Zamagni E, Nanni C, Patriarca F et al. A prospective comparison of 18F- fluorodeoxyglucose positron emission tomography- computed tomography, magnetic resonance imaging and whole- body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007; 92: 50– 55.

14. Lecouvet FE, Malghem J, Michaux L et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Brit J Haematol 1999; 106: 35– 39.

15. Nekula J, Mysliveček M, Bačovský J et al. Magnetická rezonance a scintigrafie 99mTc- MIBI v diagnostice a sledování terapie mnohočetného myelomu. Čes Radiol 2004; 58: 65– 70.

16. Weininger M, Lauterbach B, Knop S et al. Whole- body MRI of multiple myeloma: Comparison of different MRI sequences in assessment of different growth patterns. Eur J Radiol 2009; 69: 339– 345.

17. Greipp PR, San Miguel J, Durie BGM et al. International Staging System for multiple myeloma. J Clin Oncol 2005; 23: 3412– 3420.

18. Dimopoulos M, Terpos E, Comenzo RL et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009; 23: 1545– 1556.

19. Kreuzberg B, Ferda J. Celotělové vyšetření magnetickou rezonancí. Ces Radiol 2007; 61: 351– 363.

20. Mysliveček M, Nekula J, Bačovský J. Zobrazovací metody v diagnostice a sledování mnohočetného myelomu. Vnitř Lék 2006; 52: 46– 54.

21. Baur- Melnyk A, Buhmann S, Dürr HR et al. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 2005; 55: 56– 63.

22. Dimopoulos MA, Moulopoulos A, Smith T et al. Risk of disease progression in asymptomatic multiple myeloma. Am J Med 1993; 94: 57– 61.

23. Diamond TH, Hartwell T, Clarke W et al. Percentaneous vertebroplasy for acute vertebral body fracture and deformity in multiple myeloma: a short report. Brit J Haematol 2004; 124: 485– 487.

24. Moulopoulos LA, Dimopoulos MA, Vourtsi A et al. Bone lesions with soft- tissue mass: magnetic resonance imaging diagnosis of lymphomatous involvement of the bone marrow versus multiple myeloma and bone metastases. Leuk Lymph 1999; 34: 179– 184.

25. Walker R, Barlogie B, Haessler J et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007; 25: 1121– 1128.

26. Mechl M, Neubauer J, Krejčiřík P et al. Celotělové vyšetření pomocí magnetické rezonance se zobrazením difuze u nemocných s mnohočetným myelomem – první zkušenosti. Ces Radiol 2007; 61: 364– 369.

27. Baur- Melnyk A, Buhmann S, Becker Ch et al. Whole- body MRI versus whole- body MDCT for staging of multiple myeloma. AJR 2008; 190: 1097– 1103.

28. Hur J, Yoon CS, Ryu YH et al. Efficacy of multidetector row computed tomography of the spine in patients with multiple myeloma: Comparison with magnetic resonance imaging and fluorodeoxyglucose – positron emission tomography. J Comput Assist Tomogr 2007; 31: 342– 347.

29. Piekarek A, Sosnowski P, Nowicki A et al. Whole body MR in patients with multiple myeloma. Rep Pract Oncol Radiother 2009; 14: 80– 84.

30. Hillengass J, Fechtner K, Weber MA et al. Prognostic significance of focal lesions in whole- body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010; 28: 1606– 1610.

31. Ghanem N, Lahrmann C, Engelhardt M et al. Whole- body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol 2006; 16: 1005– 1014.

32. Pepe J, Petrucci MT, Nafroni I et al. Lumbar bone mineral density as the major factor determininy increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134: 485– 490.

33. Bellaiche L, Laredo JD, Lioté F et al. Magnetic resonance appearance of monoclonal gammopathies of unknown significance and multiple myeloma. Spine 1997; 22: 2551– 2557.

34. Vande Berg BC, Michaux L, Lecouvet FE et al. Nonmyelomatous monoclonal gammopathy: correlation of bone marrow MR images with laboratory findings and spontaneous clinical outcome. Radiology 1997; 202: 247– 251.

35. Terpos E, Ratemtulla A, Dimopoulos A et al. Risk of disease progression in asymptomatic multiple myeloma. Eyert Opin Pharmacother 2005; 6: 1127– 1142.

36. Moulopoulos LA, Dimopoulos MA, Smith TL et al. Prognostic singnificance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 1995; 13: 251– 256.

37. Mariette X, Zagdanski AM, Guernazi A et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Brit J Haematol 1999; 104: 723– 729.

38. Vytřasová M, Ščudla V, Nekula J et al. Význam magnetické rezonance při vyšetření páteře u nemocných s mnohočetným myelomem. Vnitř Lék 2001; 47: 694– 698.

39. Adam Z, Bednařík J, Neubauer J et al. Doporučení pro časné rozpoznání postižení skeletu maligním procesem a pro časnou diagnostiku mnohočetného myelomu. Vnitř Lék 2006; 52 (Suppl 2): 9– 13.

40. Vaníček J, Krupa P, Adam Z. Přínos jednotlivých zobrazovacích metod pro diagnostiku a sledování aktivity mnohočetného myelomu. Vnitř Lék 2010; 56: 585– 590.

41. Dimopoulos MA, Moulopoulos LA, Maniatis A et al. Solitary plasmocytoma of bone and asymptomatic multiple myeloma. Blood 2000; 96: 2037– 2044.